April 22nd 2025
The commitment will include new, state-of-the-art R&D facilities as well as new or expanded manufacturing sites in multiple states.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Congressional Committee Questions Mylan CEO Over EpiPen Controversy
September 21st 2016Mylan CEO Heather Bresch appeared before the House Committee on Oversight and Government Reform on Sept. 21, 2016 to explain the company’s decision to increase the price of EpiPen more than 400%. The meeting comes after multiple members of Congress raised concerns about the price of the life-saving drug, which is used to treat anaphylaxis.